TD Cowen Maintains Buy on Cytek Biosciences, Raises Price Target to $5
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
TD Cowen analyst Brendan Smith maintains Cytek Biosciences (NASDAQ:CTKB) with a Buy and raises the price target from $4 to $5.
TD Cowen analyst Brendan Smith maintains Cytek Biosciences (NASDAQ:CTKB) with a Buy and raises the price target from $4 to $5.